Vicor Technologies, Inc. Powers U.S. Sales Efforts for Its PD2i Analyzer(TM) With New Independent Sales Representatives in Territories Nationwide

BOCA RATON, FL--(Marketwire - November 02, 2010) - David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that the Company is actively recruiting new independent sales representatives across the United States to drive sales of its PD2i Analyzer™. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events, including congestive heart failure patients for cardiac death resulting from arrhythmia or pump failure, diabetics for diabetic autonomic neuropathy (DAN), and trauma victims for imminent death absent immediate lifesaving intervention.

According to Christopher Vissman, Vicor’s National Sales Manager, the Company has recruited and trained 12 new sales representatives since he joined the Company in September. These reps are targeting physicians specializing in endocrinology, internal medicine, cardiology, and family medicine in cities including Boston, MA, Springfield, MA, Annapolis, MD, Wilmington, NC, Charlotte, NC, Raleigh, NC, Atlanta, GA, Jacksonville, FL, Houston, TX, Dallas, TX, Denver, CO, and Knoxville, TN.

Mr. Vissman anticipates recruiting a minimum of 10 additional representatives by the beginning of December to cover the following territories: St. Louis, MO, Phoenix, AZ, Los Angeles, CA, San Francisco, CA, Houston, TX, Nashville, TN, Jackson, MS, Chicago, IL, Salt Lake City, UT, and Newark, NJ.

“The sales representatives Chris is recruiting have worked with companies such as St. Jude Medical, Medtronic, Biotronik, Sorin Group, GE Healthcare, Hill-Rom, Stryker, CardioDynamics, Polymedco, Becton, Dickinson and Company, Intelli-Heart, eCardio, and CarboMedics. With backgrounds like theirs, we’re confident that the members of our new sales force are well-established among the physicians we’re targeting and will have a significant impact on our revenue growth going forward. Kudos to Chris Vissman; he has made remarkable inroads in establishing a powerful sales force for our PD2i Analyzer™ in the short time he’s been with us, which complements the international distributor agreements we have signed or are in the process of negotiating,” stated Mr. Fater.

Mr. Vissman was named National Sales Manager, a new position, in mid-September. He is an accomplished sales executive with more than 20 years of building sales teams, creating winning sales strategies, and managing multiple sales channels. Most recently, he was a Principal of Medical Technologies, LLC, responsible for the hiring, training, and management of a national sales team introducing new technologies to primary care physicians, cardiologists, and endocrinologists.

About Vicor Technologies, Inc.
Vicor Technologies is a biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i®). The PD2i® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

Vicor currently has three products employing the PD2i® nonlinear algorithm. The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability; physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of cardiac death.

Vicor anticipates additional applications employing the PD2i® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer
The appearance of name-brand institutions, such as St. Jude Medical, Medtronic, Biotronik, Sorin Group, GE Healthcare, Hill-Rom, Stryker, CardioDynamics, Polymedco, Becton, Dickinson and Company, Intelli-Heart, eCardio, CarboMedics, and the U.S. Army Institute for Surgical Research, in this media release does not constitute endorsement by institutions of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to successfully complete the normal range study for PD2i®values; our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a claim for the PD2i CA™ (Cardiac Analyzer) for assessing patients undergoing tests for cardiovascular disease and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to develop additional applications for the PD2i® algorithm; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 10-22

Digg this Bookmark with del.icio.us Add to Newsvine

Technorati: biotechnology medical devices cardiac death diabetes ANS dysfunction trauma